Neuralstem Inc. (NASDAQ:CUR)

CAPS Rating: 1 out of 5

CUR News and Commentary

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

80 Outperform
17 Underperform
 

All-Star Players

9 Outperform
7 Underperform
 

Wall Street

1 Outperform
1 Underperform
 

Top CUR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

kzachmann (< 20)
Submitted December 13, 2012

The small molecules developed by CUR attack disease at the point of origin rather than just mitigation of symptoms. Eventually, once the science fine tunes the delivery system and the molecule targeting system a vast array of diseases will be helped… More

zzlangerhans (99.74)
Submitted January 12, 2017

Did you hear that? Me neither. That silence was the sound of Neuralstem not talking about NSI-566, their erstwhile lead program of stem cell therapy for ALS, spinal cord injury, and stroke. The last major development was in August 2015 when the… More

CUR VS S&P 500 (SPY)

Fools bullish on CUR are also bullish on:

Fools bearish on CUR are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CUR.

Recs

0
Member Avatar Ambizush (39.30) Submitted: 12/7/2017 11:07:23 AM : Underperform Start Price: $2.06 CUR Score: +50.83

I bought it, so it has to go down.

Recs

1
Member Avatar zzlangerhans (99.74) Submitted: 1/12/2017 6:56:12 PM : Underperform Start Price: $4.31 CUR Score: +98.35

Did you hear that? Me neither. That silence was the sound of Neuralstem not talking about NSI-566, their erstwhile lead program of stem cell therapy for ALS, spinal cord injury, and stroke. The last major development was in August 2015 when the company revealed results of the phase II ALS trial showing that patients who did less poorly did better than the ones who did more poorly. Yeah.

In late 2016, Neuralstem sold a huge pile of common and preferred stock to some Chinese pharmaceutical outfit for 20M to keep the lights on in 2017. That will get them through the readout of a placebo-controlled trial of mysterious compound NS-189 for major depression in H2 2017, unless there's a delay which is very possible. I have very low expectations for this trial to be successful, given the difficulty larger pharma companies have had showing improvement over placebo in MDD using well-characterized pathways.

The reverse split and a subsequent attempt to turn Neuralstem into another low-float momo flier have created fertile ground for a red thumb. A couple of days ago, the share price spiked over 6. Compare that to the valuation of 3.4 (split-adjusted) established by the Chinese equity investment. Do the Chinese want to flip or hold? Who knows. Either way, I haven't been impressed by Chinese ventures into the equity of companies like Celsion in the past.

Recs

0
Member Avatar DigitalDisco (94.39) Submitted: 1/9/2017 12:29:52 PM : Underperform Start Price: $3.66 CUR Score: +93.40

reverse split

Leaderboard

Find the members with the highest scoring picks in CUR.

Score Leader

longtermgrowth09

longtermgrowth09 (< 20) Score: +249.79

The Score Leader is the player with the highest score across all their picks in CUR.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
longtermgrowth09 < 20 8/3/2010 Underperform 5Y $32.37 -96.35% +153.43% +249.79 0 Comment
justicebdone 23.35 5/3/2010 Underperform 3W $37.57 -96.86% +138.78% +235.64 0 Comment
mjbizdev 22.78 11/12/2012 Underperform 5Y $12.74 -90.74% +105.69% +196.42 0 Comment
Deathscythe22 < 20 10/8/2012 Underperform 3W $17.42 -93.23% +95.78% +189.01 0 Comment
IdahoInvestor 30.88 9/6/2012 Underperform 5Y $8.65 -86.35% +101.09% +187.44 0 Comment
rwpaules 75.46 9/14/2012 Underperform 1Y $15.86 -92.56% +93.25% +185.81 0 Comment
pro64grammer 28.96 9/9/2013 Underperform 5Y $28.86 -95.91% +70.05% +165.96 0 Comment
jasonrivera < 20 1/13/2016 Underperform 5Y $9.75 -87.90% +50.06% +137.95 0 Comment
JoeySolitro3 98.98 11/23/2015 Underperform 5Y $14.30 -91.75% +35.87% +127.62 0 Comment
zzlangerhans 99.74 1/13/2017 Underperform 1Y $4.31 -72.62% +25.73% +98.35 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackUltraLong < 20 1/7/2013 Underperform NS $17.16 -93.12% +95.45% +188.57 1 Comment
TrackMorganJos 82.19 9/22/2011 Outperform NS $19.63 -93.99% +152.15% -246.14 0 Comment

Featured Broker Partners


Advertisement